PDK1 Knockout HAP1 Cell Line

Important nomenclature clarification: PDK1 (Gene ID 5163) is **pyruvate dehydrogenase kinase 1**, a mitochondrial kinase that inactivates the pyruvate dehydrogenase complex by phosphorylating PDHA1. This is distinct from PDPK1 (3-phosphoinositide-dependent protein kinase-1, Gene ID 5170), an AGC-family kinase that activates AKT, S6K, and other AGC kinases — these two enzymes are frequently confused in the literature. The choice between knockout and overexpression depends on whether you are studying PDK1's role as a mitochondrial PDC-inactivating kinase or its functions in metabolic reprogramming, hypoxia response, and cancer metabolism. The Knockout line is the standard tool for asking whether PDK1 is required for PDHA1 phosphorylation — PDK1 is the only PDK isoform that phosphorylates PDHA1 at S232 in addition to the shared S293 and S300 sites. For cancer metabolism research, the EDITGENE PDK1 Knockout in HAP1 enables study of PDK1-specific contributions to Warburg metabolism — PDK1 is upregulated under hypoxia (HIF-1 target) and contributes to lactate generation by suppressing PDC. PDK paralog (PDK2, PDK3, PDK4) expression analysis is essential given functional overlap. Rescue with wild-type or kinase-dead PDK1 is the standard specificity control. The knockout is valuable for studying dichloroacetate (DCA) and other PDK inhibitor specificity in cancer metabolic therapy.

Primary applications: • PDHA1 phosphorylation: phospho-PDHA1 S232 (PDK1-specific site) and S293/S300 Western blot analysis to characterize PDK1-specific contributions. • Warburg metabolism: lactate generation, oxygen consumption (Seahorse OCR/ECAR), and metabolic flexibility assessment in PDK1-null cells. • Hypoxia response: HIF-1α stabilization and PDK1 upregulation under hypoxic conditions — PDK1 is a major HIF target. • PDK inhibitor pharmacology: dichloroacetate (DCA) and other PDK inhibitors specificity testing — DCA is being investigated for cancer metabolic therapy and PDC deficiency. EDITGENE recommends this model for researchers investigating PDK1-specific PDC regulation, cancer metabolic reprogramming, and PDK-targeted therapeutic development.

Yes. PDK1 rescue experiments require attention to mitochondrial targeting and disambiguation from PDPK1: • Construct design: use a codon-modified PDK1 (Gene ID 5163, pyruvate dehydrogenase kinase 1) sequence with a small C-terminal tag (FLAG, HA). PDK1 has N-terminal mitochondrial targeting sequence — N-terminal tags must not disrupt import. Verify the cDNA encodes the mitochondrial kinase, not PDPK1. • Mitochondrial localization validation: confirm mitochondrial matrix localization by appropriate compartment markers. • Kinase-dead rescue: ATP-binding residue mutations abolish PDK1 catalytic activity. • Functional readout: rescue should restore phospho-PDHA1 (S232, S293, S300) and PDC inhibition. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.